print version

Colorectal cancer is the third most commonly diagnosed cancer in males and the second in females in the developed world. Currently, an important treatment for these patients is the drug AvastinĀ® (bevacizumab), which inhibits tumour blood vessel formation and thus prevents tumour growth.

AngioPredict will identify biomarkers to predict whether individual metastatic colorectal cancer patients will respond positively to AvastinĀ® combination therapy. This will prevent unnecessary treatment, save critical time in patient care and improve quality of life. 


Attached Documents

PDF icon AngioPredict Project Overview (AngioPredict_brochure.pdf | 562 kB)